Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced that the first patient has been treated in its U.S. multi-center pancreatic cancer pilot study, known as IMPACT (Intratumoral Pancreatic Alpha Combination Trial), evaluating the safety, feasibility and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma.

Sept. 4, 2025 — 4DMedical, a global medical technology company, has announced U.S. Food and Drug Administration (FDA) 510(k) clearance for CT:VQ, the world's the company's non-contrast, ventilation–perfusion (V/Q) imaging solution. In parallel, the U.S. Centers for Medicare & Medicaid Services (CMS) has confirmed reimbursement for CT:VQ under Category III CPT codes; this payment is in addition to existing reimbursement for the underlying chest CT.

Sept. 2, 2025 — As American hospitals continue to grapple with an increasing shortage of specialized medical imaging technologists, a new partnership is turning a little-known hardware device into a critical lifesaving tool. Currently, the U.S. is facing a radiographer staffing shortfall of 15.6%, with experts continuing to sound the alarm.

Aug. 29, 2025 — GE HealthCare has launched Vivid Pioneer, its most advanced, ultra-premium and adaptive cardiovascular ultrasound system yet, completely redesigned to support clinicians with imaging in 2D, 4D and color flow, streamlined workflow, and enhanced diagnostic confidence. The ultrasound system recently received CE Mark and U.S. FDA 510(k) clearance.

The Vivid Pioneer is on display during the European Society of Cardiology 2025, Aug. 29–Sept., 1 in Madrid, Spain.